Antibodies blocking the interaction between PD-L1 and its receptor PD-1, expressed by cytotoxic CD8+ T cells, prevented T cell anergy and restored anti-tumor activity, and have been approved for HCC treatment. Here, CD8A is linked to neoplasm.